Distributed Pharmacodynamic Architecture in Multi-Component Herbal Formulations: A Flux-Based Framework for Redox-Heterogeneous Diseases.

Cancer is increasingly recognized as a systems-level disorder characterized not only by genetic alterations but also by persistent dysregulation of stress-adaptive signaling networks integrating inflammation, metabolism, immune modulation, and cellular plasticity. Within this framework, reactive oxygen species (ROS) function as flux-dependent regulators of signaling fidelity rather than merely cytotoxic byproducts. Therapeutic strategies centered on single high-affinity targets or indiscriminate antioxidant suppression often fail to achieve durable responses in redox-heterogeneous and inflammation-driven malignancies. Multi-component herbal formulations represent chemically diverse systems capable of distributed pharmacodynamic modulation across interconnected signaling nodes and heterogeneous pharmacokinetic exposure profiles arising from multi-constituent absorption kinetics. Ojeoksan (Wu Ji San), a classical East Asian multi-herbal decoction, has accumulated experimental and clinical evidence demonstrating regulatory effects on inflammatory mediators, metabolic homeostasis, mitochondrial stress responses, and immune signaling pathways. Rather than inducing abrupt pathway inhibition, OJS appears to exert graded, parallel modulation across multiple redox-sensitive axes. Here, we reinterpret OJS within a flux-based pharmacological framework, conceptualizing it as a distributed redox-buffering architecture rather than a direct cytotoxic agent. By integrating Korean and Chinese research traditions with systems-level redox modeling and electrochemical perspectives, we propose that multi-component formulations may enhance pharmacodynamic robustness through controlled modulation of ROS amplitude and multi-node buffering while temporally distributing pharmacodynamic signals through multi-component pharmacokinetic synchronization. From a formulation science standpoint, such distributed electrochemical diversity may expand therapeutic tolerance windows and mitigate compensatory pathway escape in chronic inflammatory and therapy-resistant cancers. This perspective supports repositioning multi-herbal formulations as network-aligned pharmacological systems compatible with modern molecular pharmacology formulation-level design principles and rational combination therapy strategies.